Joshua A. Hill, MD, Bryan Mayer, PhD, Hu Xie, MS, Wendy M

Slides:

Advertisements

Similar presentations

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Advertisements

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation Navneet S. Majhail, MD, MS, Tejo.

How to Treat MDS without Stem Cell Transplantation

Prevalence of Chromosomally Integrated Human Herpesvirus 6 in Patients with Human Herpesvirus 6–Central Nervous System Dysfunction Joshua A. Hill, Ruth.

Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients.

Kidney and Bladder Outcomes in Children with Hemorrhagic Cystitis and BK Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation Benjamin.

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma Taewoong Choi, Murali K. Kodali, Wen-Kai Weng

Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.

Correlation and Agreement of Handheld Spirometry with Laboratory Spirometry in Allogeneic Hematopoietic Cell Transplant Recipients Guang-Shing Cheng,

Hepatitis Due to Human Herpesvirus 6 after Hematopoietic Stem Cell Transplantation Joshua A. Hill, MD, Danielle Zerr, MD, MPH, Ruth Hall Sedlak, PhD,

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Efficiency and Risk Factors for CMV Transmission in Seronegative Hematopoietic Stem Cell Recipients Steven A. Pergam, Hu Xie, Ravinder Sandhu, Margaret.

Vitamin A Deficiency Is Associated with Increased Risk of Acute Graft Versus Host Disease in Children Dana T. Lounder, MD, Sonata Jodele, MD, Pooja Khandelwal,

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Systematic Anti-Mold Prophylaxis Results in Very Low Incidence of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia.

Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation Filippo Milano, MD, PhD, Brent.

Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 Andrew M. Brunner,

Outcome of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Hematopoietic Cell Transplant Recipients Receiving Aerosolized Ribavirin: Significance.

Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation

Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:

Mortality Rates of Human Metapneumovirus and Respiratory Syncytial Virus Lower Respiratory Tract Infections in Hematopoietic Cell Transplantation Recipients

Access to Hematopoietic Cell Transplantation in the United States

Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance.

Incidence and Risk Factors for Central Nervous System Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia

Let Them Eat! Comparing a Neutropenic Diet to a Food Safety Based Diet in Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Cynthia.

David C. Yao, MD, PhD, Paolo Caimi, MD, Hillard M

Human Rhinovirus RNA Detection in the Lower Respiratory Tract of Hematopoietic Cell Transplant Recipients: Association with Mortality Sachiko Seo, Emily.

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Outcomes with Pre-Emptive Rituximab (pre-R) Treatment for Epstein-Barr Viremia (EBV) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Tania.

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia Hien K. Duong, MD, Mojtaba Akhtari, MD, Kwang Woo Ahn, PhD, Zhen-Huan.

Danielle M. Zerr, Michael Boeckh, Colleen Delaney, Paul J

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes Without Adding Serious Toxicity When Compared to Fludarabine/Melphalan.

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Evaluating the Impact of Antithymocyte Globulin on Lung Function at 1 Year after Allogeneic Stem Cell Transplantation Filippo Milano, Margaret A. Au,

Tyler G. Ketterl, Eric J. Chow, Wendy M

Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection Ron Mihelic,

Claudio Brunstein, MD, PhD, Keli Hippen, Todd E

Late-Onset Colitis after Cord Blood Transplantation Is Consistent with Graft-Versus-Host Disease: Results of a Blinded Histopathological Review Filippo.

Trial in Progress: Gravitas-301, a Randomized, Double-Blind Phase 3 Study of Itacitinib or Placebo with Corticosteroids (CS) for the First-Line Treatment.

The Influence of Stem Cell Source on Chronic-GvHD Free, Leukemia Free Transplant Survival in Pediatric Patients with Acute Myeloid Leukemia Amy K. Keating,

Biology of Blood and Marrow Transplantation

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Graft-Versus-Host Disease Targets Granulosa Cell of Ovarian Follicle and Causes Infertility after Allogeneic Hematopoietic Stem Cell Transplantation

Patient Self-Perceived Burden and Caregiver Burden in Recipients of Hematopoietic Stem Cell Transplantation: A Longitudinal Study Examining Gender Differences

Long-Term Outcomes of Critically Ill Adult Allogeneic Hematopoietic Stem Cell Recipients Prakash Vishnu, Udit Roy, Pramod Guru, Colleen Thomas, Candido.

Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients LeAnne Kennedy, Marie Cavalier,

Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution! Anant Vatsayan, MD, Linda.

Similar Invasive Fungal Infection Rates and Survival after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Bone Marrow or.

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation? Melhem.

Early Results of Phase II Study Using OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HCT-TMA) Samer.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Stratification of Allogeneic Hematopoietic Cell Transplant Patients by Risk of Developing Veno-Occlusive Disease: A Model for Assigning a Risk Score

Gerard Socié, K. Scott Baker, Smita Bhatia

Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

Reduced Intensity Versus Myeloablative Conditioning Allogeneic HCT for Relapsed/Refractory Lymphoma: Applying Refined Disease Risk Index (DRI) to Improve.

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

Mammen Chandy Biology of Blood and Marrow Transplantation

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Pre-Transplant Comorbidity As an Outcome Predictor in Hematopoietic Cell Transplantation for Severe Aplastic Anemia SungNam Lim, Je-Hwan Lee, MD, PhD,

Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation

Longitudinal Assessment of Morbidity and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Retrospective Analysis of a.

Mary Eapen Biology of Blood and Marrow Transplantation

Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma Luciano J. Costa, Jia-Xing Huang, Parameswaran.

Presentation transcript:

CMV, BKV, HHV-6B, AdV, and EBV Kinetics after Allogeneic Hematopoietic Cell Transplantation Joshua A. Hill, MD, Bryan Mayer, PhD, Hu Xie, MS, Wendy M. Leisenring, Meei-Li Huang, Terry L. Stevens-Ayers, Filippo Milano, MD, PhD, Colleen Delaney, MD, MSc, Keith R. Jerome, MD, PhD, Danielle Zerr, MD, MPH, Garrett Nichols, MD, MS, Michael J. Boeckh, MD, Joshua T. Schiffer, MD, MS Biology of Blood and Marrow Transplantation Volume 22, Issue 3, Pages S165-S166 (March 2016) DOI: 10.1016/j.bbmt.2015.11.527 Copyright © 2016 Terms and Conditions

Figure 1 Proportion of patients with any s pecific virus detected at any time through day 100, subdivided by most frequent occurrences of s ingle or concurrent viral detection Biology of Blood and Marrow Transplantation 2016 22, S165-S166DOI: (10.1016/j.bbmt.2015.11.527) Copyright © 2016 Terms and Conditions

Figure 2 Linear regression models for mean population viral load stratified by A) acute GVHD grade ≥3 and B) HCT type. Adjusted for sex, race, age, disease risk; Conditioning, and concurrent detection of other viruses. * = p < 0.05, ** = p<0.001 Biology of Blood and Marrow Transplantation 2016 22, S165-S166DOI: (10.1016/j.bbmt.2015.11.527) Copyright © 2016 Terms and Conditions

Figure 3 Proportion of patients with detection of each virus by week after HCT Biology of Blood and Marrow Transplantation 2016 22, S165-S166DOI: (10.1016/j.bbmt.2015.11.527) Copyright © 2016 Terms and Conditions